Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device

ORAGENICS INC

Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.
Signed LOI to license a complementary CNS medical device; expands addressable indication set beyond ONP-002.
Cash balance $6.1M as of Q1 2026; R&D expenses $0.6M (up 89% YoY); G&A $1.6M (down 4% YoY).
Targets Type C meeting with FDA in Q2 2026, IND submission by end of 2026, Phase IIa data readout in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.